Skip to main content
. 2021 Nov 12;7(6):e633. doi: 10.1212/NXG.0000000000000633

Figure 4. Correlating Longitudinal miRNA Expression to UPDRS II + III.

Figure 4

(A) The sum of Unified Parkinson's Disease Rating Score (UPDRS) II (motor) and III (activities of daily living) and at 0, 12, and 27 months ±SD. The difference in scores is shown below in the table. (B) Heatmap of the correlation between 12-month and longitudinal changes in UPDRS II-III and longitudinal changes in miRNAs were computed using Spearman rank correlations. Placebo group miRNAs that highly correlate with UPDRS II + III (r > 0.5, p < 0.05) are outlined by a dotted line and are shown to the right. Twenty-seven–month correlation when placebo was transitioned to nilotinib, 150 or 300 mg, for the second year (right). (C) KEGG, Reactome, and WikiPathway enrichment analysis of gene regulation by miRNAs that highly correlate with UPDRS II + III in placebo.